NCT06941818View on ClinicalTrials.gov

HS-IT101 Injection in the Treatment of Advanced Melanoma

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2027

Conditions
Advanced Melanoma
Interventions
DRUG

HS-IT101 Injection

Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.

Trial Locations (1)

Unknown

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Qingdao Sino-Cell Biomedicine Co., Ltd.

INDUSTRY